Publication:
Diagnosis and treatment of cardiac amyloidosis. A position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases

Simple item page
dc.contributor.authorGarcia-Pavia, Pablo
dc.contributor.authorRapezzi, Claudio
dc.contributor.authorAdler, Yehuda
dc.contributor.authorArad, Michael
dc.contributor.authorBasso, Cristina
dc.contributor.authorBrucato, Antonio
dc.contributor.authorBurazor, Ivana
dc.contributor.authorCaforio, Alida L. P.
dc.contributor.authorDamy, Thibaud
dc.contributor.authorEriksson, Urs
dc.contributor.authorFontana, Marianna
dc.contributor.authorGillmore, Julian D.
dc.contributor.authorGonzalez-Lopez, Esther
dc.contributor.authorGrogan, Martha
dc.contributor.authorHeymans, Stephane
dc.contributor.authorImazio, Massimo
dc.contributor.authorKindermann, Ingrid
dc.contributor.authorKristen, Arnt V.
dc.contributor.authorMaurer, Mathew S.
dc.contributor.authorMerlini, Giampaolo
dc.contributor.authorPantazis, Antonis
dc.contributor.authorPankuweit, Sabine
dc.contributor.authorRigopoulos, Angelos G.
dc.contributor.authorLinhart, Ales
dc.date.accessioned2026-02-24T10:49:07Z
dc.date.available2026-02-24T10:49:07Z
dc.date.issued2021-04-23
dc.description.peerreviewedSí
dc.description.tableofcontentsP.G.P. reports grant support from Institutode Salud Carlos III (PI20/01379); speaking fees from Pfizer, Eidos,Alnylam, and Akcea; consulting fees from Pfizer, Eidos, Neuroin-mmune, Alnylam, Prothena and Akcea; research support to hisinstitution from Pfizer, Eidos and Alnylam. C.R. reports speakingfees from Pfizer, Alnylam, and Akcea; consulting fees from Pfizer,Alnylam, Prothena and Akcea; institutional research grants fromPfizer. M.A. reports receiving an advisory board fee and a researchgrant from Pfizer and from Sanofi Genzyme. U.E. reports con-sulting fees and grant support from Pfizer and Sanofi; institutionalgrants from Pfizer. M.F. is supported by a British Heart Founda-tion Intermediate Clinical Research Fellowship (FS/18/21/33447)and reports consulting fees from Pfizer, Akcea, Ionis, Alnylam,Alexion, Sanofi and research grant from Pfizer. J.D.G. reports con-sulting and speaking fees from Pfizer, Akcea, Alnylam, and Eidos.E.G.L. reports grant support from Instituto de Salud Carlos III(PI18/0765); speaking fees from Pfizer and Alnylam; consulting feesfrom Pfizer and Proclara; research support to her institution fromPfizer, Eidos and Alnylam. M.G. reports grant/clinical trial supportfrom Alnylam, Eidos, Prothena, and Pfizer. I.K. reports speakingfees from Akcea Therapeutics Germany and Pfizer; consulting feesfrom Akcea Therapeutics Germany. A.V.K. reports consulting feesfrom Pfizer, Akcea, Alnylam, and Neurimmune and speaking feesfrom Pfizer, Akcea, and Alnylam. M.S.M. reports grant support fromNational Institutes of Health [R01HL139671-01], [R21AG058348]and [K24AG036778], consulting income from Pfizer, GSK, EIdos,Prothena, Akcea and Alnylam, and institution received clinical trialfunding from Pfizer, Prothena, Eidos and Alnylam. A.G.R. reportshonoraria for presentations from AstraZeneca. A.L. reports speak-ing fees from Pfizer; consulting fees from Pfizer, Alnylam. All otherauthors have nothing to disclose.
dc.identifier.citationEur J Heart Fail. 2021 Apr;23(4):512-526.
dc.identifier.journalEuropean Journal of Heart Failure
dc.identifier.urihttps://hdl.handle.net/20.500.12105/27266
dc.language.isoeng
dc.publisherElsevier
dc.relation.isreferencedbyPubMed
dc.relation.publisherversion10.1002/ejhf.2140
dc.repisalud.institucionCNIC
dc.rights.accessRightsopen access
dc.titleDiagnosis and treatment of cardiac amyloidosis. A position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases
dc.typeresearch article
dc.type.hasVersionVoR
dspace.entity.typePublication

Files

Original bundle

Now showing 1 - 1 of 1
Thumbnail Image
Name:
Diagnosis and treatment of cardiac amyloidosis_Eur J Heart Fail_2021.pdf
Size:
8.72 MB
Format:
Adobe Portable Document Format
Download

Collections

Grupos de investigación